BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37326105)

  • 1. Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?
    Meissner M; Napolitano A; Thway K; Huang P; Jones RL
    Expert Opin Pharmacother; 2023; 24(12):1395-1401. PubMed ID: 37326105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives.
    Simeone N; Frezza AM; Zaffaroni N; Stacchiotti S
    Future Oncol; 2021 Apr; 17(10):1253-1263. PubMed ID: 33289402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
    Touati N; Schöffski P; Litière S; Judson I; Sleijfer S; van der Graaf WT; Italiano A; Isambert N; Gil T; Blay JY; Stark D; Brodowicz T; Marréaud S; Gronchi A
    Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):448-454. PubMed ID: 29550245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and advancing systemic treatment options for soft tissue sarcomas.
    Harris SJ; Benson C; Jones RL
    Expert Opin Pharmacother; 2015; 16(13):2023-37. PubMed ID: 26255951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
    Gounder M; Schöffski P; Jones RL; Agulnik M; Cote GM; Villalobos VM; Attia S; Chugh R; Chen TW; Jahan T; Loggers ET; Gupta A; Italiano A; Demetri GD; Ratan R; Davis LE; Mir O; Dileo P; Van Tine BA; Pressey JG; Lingaraj T; Rajarethinam A; Sierra L; Agarwal S; Stacchiotti S
    Lancet Oncol; 2020 Nov; 21(11):1423-1432. PubMed ID: 33035459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs.
    Wagner A
    J Natl Compr Canc Netw; 2007 Apr; 5(4):401-10. PubMed ID: 17442231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.
    Wisdom AJ; Mowery YM; Riedel RF; Kirsch DG
    Cancer; 2018 Oct; 124(19):3819-3829. PubMed ID: 29723407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelioid Sarcoma-From Genetics to Clinical Practice.
    Czarnecka AM; Sobczuk P; Kostrzanowski M; Spalek M; Chojnacka M; Szumera-Cieckiewicz A; Rutkowski P
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapies in soft tissue sarcoma.
    Vincenzi B; Frezza AM; Santini D; Tonini G
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):237-48. PubMed ID: 20465449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting epigenetics in sarcomas through EZH2 inhibition.
    Italiano A
    J Hematol Oncol; 2020 Apr; 13(1):33. PubMed ID: 32264965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy in adult soft tissue sarcoma.
    Jain A; Sajeevan KV; Babu KG; Lakshmaiah KC
    Indian J Cancer; 2009; 46(4):274-87. PubMed ID: 19749457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targets and novel therapeutic avenues in soft-tissue sarcoma.
    Elkrief A; Alcindor T
    Curr Oncol; 2020 Feb; 27(Suppl 1):34-40. PubMed ID: 32174756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current state-of-the-art systemic therapy for pediatric soft tissue sarcomas.
    Ray A; Huh WW
    Curr Oncol Rep; 2012 Aug; 14(4):311-9. PubMed ID: 22535507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of systemic therapy in sarcoma.
    Constantinidou A; Pollack S; Loggers E; Rodler E; Jones RL
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):211-23. PubMed ID: 23406562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer medical therapies for metastatic soft tissue sarcoma.
    Tiwari A; Gupta VG; Bakhshi S
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):257-270. PubMed ID: 28103739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel treatment strategies for soft tissue sarcoma.
    Kasper B; Gil T; D'Hondt V; Gebhart M; Awada A
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):9-15. PubMed ID: 17141519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials.
    Spunt SL; Francotte N; De Salvo GL; Chi YY; Zanetti I; Hayes-Jordan A; Kao SC; Orbach D; Brennan B; Weiss AR; van Noesel MM; Million L; Alaggio R; Parham DM; Kelsey A; Randall RL; McCarville MB; Bisogno G; Hawkins DS; Ferrari A
    Eur J Cancer; 2019 May; 112():98-106. PubMed ID: 30954717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy in bone and soft tissue sarcoma in children and adolescents.
    Thompson PA; Chintagumpala M
    Curr Oncol Rep; 2012 Apr; 14(2):197-205. PubMed ID: 22302601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of adjuvant chemotherapy in the management of sarcomas in children.
    Donaldson SS
    Cancer; 1985 May; 55(9 Suppl):2184-97. PubMed ID: 3884137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy in pediatric-type soft-tissue sarcoma.
    Ingley KM; Cohen-Gogo S; Gupta AA
    Curr Oncol; 2020 Feb; 27(Suppl 1):6-16. PubMed ID: 32174753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.